Loading...
XNASWVE
Market cap2.06bUSD
Dec 20, Last price  
13.51USD
1D
2.43%
1Q
137.85%
Jan 2017
-48.34%
IPO
-15.56%
Name

WAVE Life Sciences Ltd

Chart & Performance

D1W1MN
XNAS:WVE chart
P/E
P/S
18.19
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
29.64%
Rev. gr., 5y
51.04%
Revenues
113m
+3,005.10%
00152,0001,485,0003,704,00014,414,00015,983,00020,077,00040,964,0003,649,000113,305,000
Net income
-58m
L-64.46%
-3,318,000-5,229,000-19,200,000-55,401,000-102,035,000-146,653,000-179,496,000-149,910,000-122,245,000-161,823,000-57,513,000
CFO
-19m
L-84.79%
-3,551,000-4,426,000-12,527,000-31,872,000-83,671,000-22,862,000-188,231,000-115,982,000-88,993,000-127,781,000-19,431,000
Earnings
Mar 04, 2025

Profile

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
IPO date
Nov 11, 2015
Employees
250
Domiciled in
SG
Incorporated in
SG

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
113,305
3,005.10%
3,649
-91.09%
40,964
104.03%
Cost of revenue
190,507
176,483
289,855
Unusual Expense (Income)
NOPBT
(77,202)
(172,834)
(248,891)
NOPBT Margin
Operating Taxes
(677)
681
(204)
Tax Rate
NOPAT
(76,525)
(173,515)
(248,687)
Net income
(57,513)
-64.46%
(161,823)
32.38%
(122,245)
-18.45%
Dividends
Dividend yield
Proceeds from repurchase of equity
131,277
67,188
54,970
BB yield
-24.50%
-12.17%
-33.78%
Debt
Debt current
13,428
5,496
4,961
Long-term debt
57,522
69,732
54,871
Deferred revenue
15,601
79,774
77,479
Other long-term liabilities
8,064
7,874
Net debt
(129,401)
(16,929)
(94,383)
Cash flow
Cash from operating activities
(19,431)
(127,781)
(88,993)
CAPEX
(1,115)
(1,361)
(560)
Cash from investing activities
(1,115)
(1,255)
(560)
Cash from financing activities
132,534
67,188
55,828
FCF
(68,119)
(176,998)
(243,901)
Balance
Cash
200,351
88,497
150,564
Long term investments
3,660
3,651
Excess cash
194,686
91,975
152,167
Stockholders' equity
(81,733)
(156,659)
(47,608)
Invested Capital
183,670
237,020
195,375
ROIC
ROCE
EV
Common stock shares outstanding
106,097
78,856
51,826
Price
5.05
-27.86%
7.00
122.93%
3.14
-60.10%
Market cap
535,791
-2.93%
551,991
239.20%
162,732
-47.29%
EV
414,264
542,936
76,223
EBITDA
(67,996)
(162,720)
(239,056)
EV/EBITDA
Interest
1,578
Interest/NOPBT